hotspot -WSS

hotspot

author：hotspot 2025-10-02 13:31:43 Page View：48

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In the gardens at Boston Children's Hospital, families find sanctuary
Next article： Psychedelics group wrestles with new pharma identity

knowledge

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

New Alzheimer's drugs heat up race for early detection blood tests

MarionBerard/AFP/GettyImagesWiththeadventofdisease-modifyingAlzheimer’sdrugs,everyoneintheworldofAlz

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

Dems pitch expanding Medicare power to negotiate drug prices

Reps.RichardNeal(D-Mass.),Rep.FrankPallone(D-N.J.),andRep.JohnYarmuth(D-Ky.)JoeRaedle/GettyImagesWAS

hotspot

focus

knowledge

Dems pitch expanding Medicare power to negotiate drug prices